Public Disclosure Authorized

Public Disclosure Authorized

INTEGRATED SAFEGUARDS DATA SHEET
CONCEPT STAGE

Report No.: AC519

Date ISDS Prepared/Updated: December 22, 2003

I. BASIC INFORMATION

A. Basic Project Data

Country: Central Asia	Project ID: P087003
Project Name: Central Asia AIDS Control Project	Task Team Leader: Joana Godinho
Estimated Appraisal Date: December 2004	Estimated Board Date: April 2005
Managing Unit: ECSHD	Lending Instrument: Specific Investment Loan
Sector: Health (100%)	Theme: Health system performance (P); Other communicable diseases (P); Other human development (P); Child health (S); Population and reproductive health (S)
Safeguard Policies Specialists in the task team:	
Loan/Credit amount ($m.): IDAH: 25	
Other financing amounts by source: 5 ($m), Government	

B. Project Objectives

The proposed regional project would aim at contributing to revert the trend in rapid growth of HIV/AIDS incidence in Central Asia through:

(i) harmonization of **regional policy** regarding prevention and treatment of HIV/AIDS;
(ii) development of regional partnerships between different sectors and agencies;
(iii) development and harmonization of **surveillance** on HIV/AIDS, STIs and TB;
(iv) **capacity building** on prevention and treatment of HIV/AIDS; and
(v) **prevention and treatment** of HIV/AIDS.

C. Project Description

The following project components will be further discussed with counterparts:

(i) **Policy development and monitoring & evaluation** (estimated cost $2 million). This component would support the Regional AIDS Committee that would steer project preparation and implementation, and coordinate the strategic approaches and policies concerning HIV/AIDS in Central Asia,

including legislation affecting highly vulnerable groups; anti-discrimination laws; and policy regarding use of anti-retroviral drugs. This component would develop a regional framework to establish common approaches for registration, procurement, quality assurance and price negotiations for pharmaceuticals and related medical technology and supplies as they relate to HIV/AIDS prevention and treatment. The component would also establish monitoring and evaluation of regional progress on prevention and treatment of HIV/AIDS.

(ii) **Development of partnerships between different sectors and agencies** (estimated cost $5 million). This component would aim at increasing civil society participation on HIV/AIDS control in Central Asia. It would support the participation of governmental, private sector and non-governmental organizations in regional activities promoted by the Regional AIDS Committee. It may be organized as a fund that would finance regional activities on a demand-driven and competitive basis.

(iii) **Strengthening epidemiological surveillance and lab capacity** (estimated cost $5 million). This component would upgrade and harmonize surveillance of HIV/AIDS, STIs and TB in Central Asia, especially focusing on sentinel surveillance[1]. The component would support the development of regional protocols for establishing regional information and data standards, common forms and reporting procedures.

(iv) **Building regional capacity to tackle the epidemic** (estimated cost $7 million), including leadership, policy development and surveillance; outreach work with groups at risk, and updated treatment protocols; and project management, including financial management, procurement, and monitoring and evaluation. The component would support the development of a regional School of Public Health.

(v) **Prevention and control of HIV/AIDS** (estimated cost $5 million). This component would support the development of regional outreach work with mobile highly vulnerable groups and vulnerable groups (CSWs, truck drivers, migrant workers, army, etc); and dissemination of guidelines regarding blood safety and of evidence-based protocols of care for PMTCT and for treatment of PLHWA.

(vi) **Project Management** (estimated cost $1 million). Several options are being considered for project management and implementation of this regional project

[1] **Sentinel surveillance** allows monitoring of the population's epidemic through small-scale sampling of specific subgroups. It can include special studies of HIV prevalence in highly vulnerable populations such as IDUs, anonymous and unlinked testing of blood obtained for other purposes such as in blood donations, and testing of institutionalized or military populations on a regular basis.

D. Project location

Central Asia

E. Borrower's Institutional Capacity for Safeguard Policies

[Guideline: Based on past experience and other available information]

II. SAFEGUARD POLICIES THAT MIGHT APPLY

Applicable?	Safeguard Policy If Applicable, How Might It Apply?
[N]	**Environmental Assessment (OP/BP 4.01)**
[N]	**Natural Habitats (OP/BP 4.04)**
[N]	**Pest Management (OP 4.09)**
[N]	**Involuntary Resettlement (OP/BP 4.12)**
[N]	**Indigenous Peoples (OD 4.20)**
[N]	**Forests (OP/BP 4.36)**
[N]	**Safety of Dams (OP/BP 4.37)**
[N]	**Cultural Property (draft OP 4.11 - OPN 11.03)**
[N]	**Projects in Disputed Areas (OP/BP/GP 7.60)***
[N]	**Projects on International Waterways (OP/BP/GP7.50)**

Environmental Assessment Category:
[ ] A [ ] B [X] C [ ] FI [ ] TBD (to be determined)

This project is likely to have minimal or no adverse environmental impacts, and it will not involve any civil works, medical waste or land acquisition

III. SAFEGUARD PREPARATION PLAN

A. Target date for the Quality Enhancement Review (QER), at which time the PAD-stage ISDS would be prepared – **March 31, 2004.**

B. For simple projects that will not require a QER, the target date for preparing the PAD-stage ISDS

C. Time frame for launching and completing the safeguard-related studies that may be needed. The specific studies and their timing[3] should be specified in the PAD-stage ISDS.

IV. APPROVALS

Signed and submitted by:		
Task Team Leader:	**Joana Godinho**	**Date**
Approved by:		
Regional Safeguards Coordinator:	**Ronald N. Hoffer**	**Date**
Comments		
Sector Manager:	**Armin H. Fidler**	**Date**
Comments		

[1]**Sentinel surveillance** allows monitoring of the population's epidemic through small-scale sampling of specific subgroups. It can include special studies of HIV prevalence in highly vulnerable populations such as IDUs, anonymous and unlinked testing of blood obtained for other purposes such as in blood donations, and testing of institutionalized or military populations on a regular basis.

[*]By supporting the proposed project, the Bank does not intend to prejudice the final determination of the parties' claims on the disputed areas

[2]Reminder: The Bank's Disclosure Policy requires that safeguard-related documents be disclosed before appraisal (i) at the InfoShop and (ii) in-country, at publicly accessible locations and in a form and language that are accessible to potentially affected